grant
High throughput multidimensional chemoproteomics for function-directed covalent target discovery
Organization UNIVERSITY OF CALIFORNIA LOS ANGELESLocation LOS ANGELES, UNITED STATESPosted 8 Aug 2025Deadline 31 Jul 2028
NIHUS FederalResearch GrantFY2025AdoptedAnti-Cancer AgentsAntineoplastic AgentsAntineoplastic DrugsAntineoplasticsAreaAssayBioassayBiochemicalBiological AssayBiologyC-K-RASCancer DrugCancer GenesCancer-Promoting GeneCancersClinicalCollaborationsCustomCysteineDNA HelicasesDNA Unwinding ProteinsDNA unwinding enzymeDataData AnalysesData AnalysisDimensionsDistalDrugsEGF ReceptorEGFRERBB ProteinEnsureEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor KinaseEpidermal Growth Factor Receptor Protein-Tyrosine KinaseEpidermal Growth Factor-Urogastrone ReceptorsEventFoundationsFutureHER1Half-CystineIndustryIsotope LabelingJAK1JAK1 geneJAK1 proteinJAK1AJak1 kinaseJanus kinase 1K-RAS2AK-RAS2BK-RasK-Ras 2AK-Ras-2 OncogeneKRASKRAS2KRAS2 geneKi-RASL-CysteineLabelLeadLibrariesMalignant NeoplasmsMalignant TumorMass Photometry/Spectrum AnalysisMass SpectrometryMass SpectroscopyMass SpectrumMass Spectrum AnalysesMass Spectrum AnalysisMedicationMedicinal ChemistryMethodsModalityModificationNeoplastic Disease Chemotherapeutic AgentsOncogene K-RasOncogenesOncogenicOxidation-ReductionPatientsPb elementPeptidesPerformancePharmaceutic ChemistryPharmaceutical ChemistryPharmaceutical PreparationsPhasePrecision cancer therapyPrecision cancer treatmentPreparationPrimary NeoplasmPrimary TumorProteinsProteomeProteomicsRASK2ReagentRedoxReportingReproducibilityResearchRisk TakingRouteSamplingSightSilanesSiteSolidStructure-Activity RelationshipTGF-alpha ReceptorTechnologyTestingTherapeuticTransforming GenesTransforming Growth Factor alpha ReceptorTriageTumor-Specific Treatment AgentsTyrosine-Protein Kinase JAK1Urogastrone ReceptorVisionWorkanti-cancer druganti-cancer researchbiomarker discoveryc-erbB-1c-erbB-1 Proteincancer researchchemical structure functionchemoproteomicscostcustomsdata acquisitiondata acquisitionsdata interpretationdetection limitdrug developmentdrug discoverydrug-like chemicaldrug-like compounddrug-like moleculedrug/agenterbB-1erbB-1 Proto-Oncogene ProteinerbBlheavy metal Pbheavy metal leadhelicaseimprovedinnovateinnovationinnovativeinsightmalignancyneoplasm/cancernew approachesnovelnovel approachesnovel strategiesnovel strategyoxidationoxidation reduction reactionprecision anticancer therapyprecision cancer therapeuticpreparationsprogramsprotein functionproto-oncogene protein c-erbB-1screeningscreeningssmall moleculestructure function relationshipsuccesstech developmenttechnology developmenttumorv-Ki-RAS2 Kirsten Rat Sarcoma 2 Viral Oncogene Homologvisual function
Description preview
PROJECT SUMMARY/ABSTRACT
Cysteine-reactive drugs are an exciting class of therapeutics that offer the benefits of high potency, occupancy
and increased selectivity. Motivated by the clinical success of recent cancer therapeutics that engage specific
cysteines, including neratinib and ibrutinib, the discovery of additional targets amenable to…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click